Randall Moreadith

Company: Serina Therapeutics

Job title: Chief Development Officer

Seminars:

Overcoming Anti-PEG Antibody Responses – a Novel PEOZ-lipid That Fails to Elicit an Immune Response to the Polymer-lipid in mRNA-LNP Formulations 9:30 am

Overcoming toxicity challenges associated with PEG lipids by altering nanoparticle formulation and design employing a novel poly (2-ethyl-2-oxazoline) PEOZ-lipid Absence of an IgM or IgG response to PEOZ-lipid Substitution of PEG-lipid with PEOZ-lipid does not alter payload properties following in vitro and in vivo transfectionRead more

day: Conference Day Two